Literature DB >> 9694139

Treatment of detrusor instability with oxybutynin rectal suppositories.

H A Winkler1, P K Sand.   

Abstract

Our aim was to determine whether oxybutynin hydrochloride suppositories can be used as a treatment for detrusor instability in patients who have not been able to tolerate oral pharmacological agents. A retrospective chart review of 25 women diagnosed with detrusor instability and treated with oxybutynin rectal suppositories was conducted. Each suppository contained 5 mg oxybutynin, 15 mg micronized Sila gel, and 1.25 g of a fatty acid base. Patients were started on one suppository twice daily and then dose titrated as tolerated. The range of the total daily dose was 5-20 mg. Nine of 25 women (36%) had greater than a 50% overall subjective improvement and 3 (12%) had some improvement. Seven of the 12 responders (58%) continued to use the suppositories for a prolonged period of time (> 90 days). The most common side effects reported were dry mouth 48% and constipation 14.3%. One patient with polymyositis developed a serious anticholinergic reaction which required hospitalization. It was concluded that patients who are unable to tolerate oral anticholinergic and antispasmodic agents for the treatment of detrusor instability may benefit from oxybutynin rectal suppositories.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694139     DOI: 10.1007/bf01982217

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  8 in total

1.  The pharmacokinetics of intravesical and oral oxybutynin chloride.

Authors:  C A Massad; B A Kogan; F E Trigo-Rocha
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

2.  The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.

Authors:  A J Tapp; L D Cardozo; E Versi; D Cooper
Journal:  Br J Obstet Gynaecol       Date:  1990-06

3.  Electromotive administration of oxybutynin into the human bladder wall.

Authors:  S M Di Stasi; A Giannantoni; R Massoud; C Cortese; G Vespasiani; F Micali
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

4.  Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability.

Authors:  K H Moore; D M Hay; A E Imrie; A Watson; M Goldstein
Journal:  Br J Urol       Date:  1990-11

5.  Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment.

Authors:  D Riva; E Casolati
Journal:  Clin Exp Obstet Gynecol       Date:  1984       Impact factor: 0.146

6.  Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial.

Authors:  D M Holmes; F J Montz; S L Stanton
Journal:  Br J Obstet Gynaecol       Date:  1989-05

7.  The pharmacokinetics of oxybutynin in man.

Authors:  J Douchamps; F Derenne; A Stockis; D Gangji; M Juvent; A Herchuelz
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Genitourinary dysfunction in a geriatric outpatient population.

Authors:  J G Ouslander; K Hepps; S Raz; H L Su
Journal:  J Am Geriatr Soc       Date:  1986-07       Impact factor: 5.562

  8 in total
  9 in total

1.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 2.  Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.

Authors:  Roger Dmochowski
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Urinary incontinence: oxybutynin topical gel for overactive bladder.

Authors:  Christopher R Chapple
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

Review 4.  [Not Available].

Authors:  Abdelmounaim Qarro; Mohammed Asseban; Khalil Bazine; Mohammed Najoui; Jamaleddine Samir; Youssef Ouhbi; Amoqrane Beddouch; Mohammed Lezrek; Mohammed Alami
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

5.  A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.

Authors:  Michael J Kennelly
Journal:  Rev Urol       Date:  2010

Review 6.  Oxybutynin: past, present, and future.

Authors:  Kelly Jirschele; Peter K Sand
Journal:  Int Urogynecol J       Date:  2012-09-14       Impact factor: 2.894

7.  The evolution of transdermal therapy for overactive bladder.

Authors:  Peter K Sand
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

8.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

Review 9.  Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder.

Authors:  Adrian Wagg
Journal:  Res Rep Urol       Date:  2012-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.